Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Ra Pharmaceuticals Inc (RARX)

Ra Pharmaceuticals Inc (RARX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,271,555
  • Shares Outstanding, K 47,329
  • Annual Sales, $ 3,000 K
  • Annual Income, $ -102,690 K
  • 60-Month Beta 1.04
  • Price/Sales 757.42
  • Price/Cash Flow N/A
  • Price/Book 8.63
Trade RARX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.99
  • Most Recent Earnings N/A on N/A
  • Next Earnings Date 05/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/20
See More
  • Average Estimate -0.62
  • Number of Estimates 2
  • High Estimate -0.61
  • Low Estimate -0.63
  • Prior Year -0.45
  • Growth Rate Est. (year over year) -37.78%

Price Performance

See More
Period Period Low Period High Performance
1-Month
40.30 +19.09%
on 03/18/20
48.02 -0.05%
on 03/31/20
+1.24 (+2.64%)
since 02/28/20
3-Month
40.30 +19.09%
on 03/18/20
48.02 -0.05%
on 03/31/20
+1.06 (+2.27%)
since 12/31/19
52-Week
19.64 +144.37%
on 06/12/19
48.02 -0.05%
on 03/31/20
+27.20 (+130.86%)
since 04/01/19

Most Recent Stories

More News
Myasthenia Gravis Treatment Market Size, Share, Trends, Analysis and Forecast 2027

The report on Myasthenia Gravis Treatment provides the clients with a comprehensive analysis of crucial driving factors, consumer behavior, growth trends, product utilization, key player analysis, brand...

ARGX : 317.11 (+0.17%)
ALPMF : 17.5000 (+0.57%)
AVDL : 7.49 (-1.19%)
BAX : 81.06 (+0.68%)
GSK : 39.53 (+0.76%)
GRFS : 15.21 (+0.40%)
MTZPY : 18.6000 (-0.13%)
NVS : 91.51 (+0.47%)
RARX : 47.99 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Myasthenia Gravis Treatment Market Global Trends, Market Share, Industry Size, Growth, Opportunities and Market Forecast 2020 to 2027

The report for Myasthenia Gravis Treatment offers an assiduous analysis of contemporary market trends, driving factors, consumer behavior, key player strategies, product usage and brand positioning. The...

ARGX : 317.11 (+0.17%)
ALPMF : 17.5000 (+0.57%)
AVDL : 7.49 (-1.19%)
BAX : 81.06 (+0.68%)
GSK : 39.53 (+0.76%)
GRFS : 15.21 (+0.40%)
MTZPY : 18.6000 (-0.13%)
NVS : 91.51 (+0.47%)
RARX : 47.99 (-0.03%)
TKPYY : 16.5900 (-0.90%)
VRX.TO : 30.80 (-3.33%)
Inozyme Pharma Announces Changes to Its Board of Directors

--Names Lynne Sullivan as Independent Director

RARX : 47.99 (-0.03%)
Is RA PHARMCTL INC (RARX) Stock Outpacing Its Medical Peers This Year?

Is (RARX) Outperforming Other Medical Stocks This Year?

RARX : 47.99 (-0.03%)
UCB Completes the Acquisition of Ra Pharmaceuticals - to Deliver Differentiated Therapies to Patients

UCB today announced that the acquisition of Ra Pharmaceuticals, Inc. has been successfully completed and Ra Pharma is now a wholly-owned subsidiary of UCB. The former Ra Pharma shareholders received US$...

RARX : 47.99 (-0.03%)
How Ra Pharmaceuticals (RARX) Stock Stands Out in a Strong Industry

Ra Pharmaceuticals (RARX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.

RARX : 47.99 (-0.03%)
Ra Pharmaceuticals Supports 13th Annual Rare Disease Day(R) and Joins Global Movement to Raise Awareness for Rare Diseases

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) is joining forces with 30 million healthcare advocates around the world for the 13th Annual Rare Disease Day(R), an awareness day dedicated to elevating public understanding...

RARX : 47.99 (-0.03%)
Ra Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Corporate Update

--First patient dosed in Phase 2 clinical trial of zilucoplan in IMNM, with top-line results expected in the second half of 2020

RARX : 47.99 (-0.03%)
CRISPR Therapeutics Proposes Changes to the Board of Directors

CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced it proposes to elect Doug Treco, Ph.D. to its...

RUBY : 21.90 (+0.27%)
CRSP : 122.67 (-1.68%)
RARX : 47.99 (-0.03%)
Ra Pharmaceuticals Announces Publication of Zilucoplan Phase 2 gMG Trial Results in JAMA Neurology

Ra Pharmaceuticals, Inc. (Nasdaq:RARX) today announced that full results from its Phase 2 clinical trial of zilucoplan in patients with generalized myasthenia gravis (gMG) were published online in JAMA...

RARX : 47.99 (-0.03%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 56% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

The market is in highly overbought territory. Beware of a trend reversal.

See More Share

Business Summary

Ra Pharmaceuticals, Inc. is a biopharmaceutical company. It involved in the discovery and development of novel therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system. Ra Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 48.02
1st Resistance Point 48.01
Last Price 47.99
1st Support Level 47.98
2nd Support Level 47.97
3rd Support Level N/A

See More

52-Week High 48.02
Last Price 47.99
Fibonacci 61.8% 37.18
Fibonacci 50% 33.83
Fibonacci 38.2% 30.48
52-Week Low 19.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar